RecruitingNot Applicable

Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases

France800 participantsStarted 2024-05-06

Plain-language summary

The aim of this project is to start a biological and clinical collection of patients presenting autoimmune, dysimmune or auto-inflammatory dermatological diseases. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies.

Who can participate

Age range

6 Years – 99 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Skin damage of documented or probable autoimmune, dysimmune or autoinflammatory origin. The patients included may be adults or children, and will be: * Patients with autoimmune bullous dermatoses (pemphigus, pemphigoid and others), * Patients with systemic autoimmune diseases associated with skin damage (lupus, scleroderma, dermatomyositis for example), * Patients with cutaneous lupus * Patients with dysimmune skin diseases (psoriasis, eczema) * Patients with immuno-induced dermatological disorders or drug dermatitis * Patients receiving, or likely to receive, new, innovative therapies (new molecule on the market, checkpoint inhibitors, gene therapy, cell therapy, etc.). Patients with dermatological damage whose autoimmune, dysimmune or auto-inflammatory origin is suspected Exclusion Criteria: * Patients under protective supervision (guardianship, curators) * Patients under 6 years old * Pregnant or breastfeeding woman

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Building a collection of biological samples and clinical-biological data from patients with autoimmune, dysimmune or auto-inflammatory dermatological disease

Timeframe: Day 0 and through study completion, an average of 1 year

Trial details

NCT IDNCT06387654

SponsorUniversity Hospital, Toulouse

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2029-04

Contact for this trial

Chloé BOST, MD, PhD

5 61 77 61 44 bost.c@chu-toulouse.fr

View on ClinicalTrials.gov More Autoimmune Bullous Dermatosis trials